Marianna L. Ianzano

Bologna, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications

Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression.

Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression.

Journal: Oncogenesis
Published: March 31, 2021

Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft.

Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft.

Journal: Scientific reports
Published: July 01, 2020

Cancer Vaccines Co-Targeting HER2/Neu and IGF1R.

Cancer Vaccines Co-Targeting HER2/Neu and IGF1R.

Journal: Cancers
Published: March 27, 2019

Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations.

Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations.

Journal: Scientific reports
Published: February 17, 2019

Immune targeting of autocrine IGF2 hampers rhabdomyosarcoma growth and metastasis.

Immune targeting of autocrine IGF2 hampers rhabdomyosarcoma growth and metastasis.

Journal: BMC cancer
Published: July 13, 2018

OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis.

OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis.

Journal: Oncoimmunology
Published: February 05, 2018

Virus-like particle display of HER2 induces potent anti-cancer responses.

Virus-like particle display of HER2 induces potent anti-cancer responses.

Journal: Oncoimmunology
Published: September 28, 2017

HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response.

HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response.

Journal: Oncotarget
Published: December 16, 2016

Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis.

Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis.

Journal: Breast cancer research : BCR
Published: August 09, 2014

Genetic prevention of lymphoma in p53 knockout mice allows the early development of p53-related sarcomas.

Genetic prevention of lymphoma in p53 knockout mice allows the early development of p53-related sarcomas.

Journal: Oncotarget
Published: August 04, 2014

Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice.

Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice.

Journal: Oncotarget
Published: December 17, 2013

Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2.

Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2.

Journal: Breast cancer research : BCR
Published: June 27, 2013
Showing 1-12 of 15

Last Updated: 09/26/2026